Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study
-
Published:2022-02
Issue:
Volume:61
Page:145-155
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Maxwell Anthony J.,
Hilton Bridget,
Clements KarenORCID,
Dodwell David,
Dulson-Cox JoanneORCID,
Kearins OliveORCID,
Kirwan Cliona,
Litherland Janet,
Mylvaganam SenthurunORCID,
Provenzano ElenaORCID,
Pinder Sarah E.,
Sawyer ElinorORCID,
Shaaban Abeer M.,
Sharma NishaORCID,
Stobart Hilary,
Wallis Matthew G.ORCID,
Thompson Alastair M.
Subject
General Medicine,Surgery
Reference27 articles.
1. The benefits and harms of breast cancer screening: an independent review;Lancet,2012
2. Overdiagnosis in breast imaging;Evans;Breast,2017
3. Addressing overtreatment of screen detected DCIS; the LORIS trial;Francis;Eur J Cancer,2015
4. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS);Hwang;BMJ Open,2019
5. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – the LORD study;Elshof;Eur J Cancer,2015
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献